In virtue of a better understanding of the molecular structure and its biological properties, FcRn has emerged as an interesting target in the treatment of myasthenia gravis and other autoimmune disorders, as it allows the reduction of autoantibodies by blocking FcRn. Here, FCGRT is linked to autoimmune disease.